EnteroBiotix Lands £19M for Landmark Microbiome Trial in IBS

GLASGOW, Scotland – April 29, 2026 – Scottish biopharmaceutical company EnteroBiotix has secured a significant £19 million ($25 million) in financing to advance a novel gut health therapy, potentially offering a breakthrough for millions suffering from Irritable Bowel Syndrome with Constipation (IBS-C). The funding will launch one of the largest clinical trials ever conducted for a microbiome-based treatment in IBS.

The investment round, led by life science investor Thairm Bio and the Scottish National Investment Bank, signals growing confidence in the company's lead candidate, EBX-102-02. This orally-delivered capsule is designed not just to manage symptoms, but to fundamentally restore the gut's complex microbial ecosystem.

The Unmet Need in Gut Health

For the estimated 10 million people in the United States and Europe living with IBS-C, the daily reality is often a debilitating cycle of abdominal pain, bloating, and chronic constipation. The condition significantly impairs quality of life, yet the current treatment landscape offers limited relief. Patients frequently navigate a frustrating trial-and-error process involving dietary changes, over-the-counter laxatives, and prescription medications.

While drugs like Linaclotide (Linzess) and Lubiprostone (Amitiza) can provide symptomatic relief for some, they often come with a trade-off. Side effects such as diarrhea and nausea are common, and the treatments primarily address the consequences of the disorder rather than its underlying cause. This leaves a significant portion of patients unsatisfied and searching for a better solution—a therapy that can modify the course of the disease itself.

It is this therapeutic gap that EnteroBiotix aims to fill. The company's approach is rooted in the growing body of evidence linking IBS to a disruption in the gut microbiome, the vast community of bacteria and other microorganisms residing in the digestive tract.

An 'Ecosystem Reset' in a Capsule

EnteroBiotix's lead candidate, EBX-102-02, is not a typical probiotic. Described as a "next-generation orally delivered full-spectrum investigational microbiome therapeutic," it is designed to deliver a diverse and stable community of microbes to reset the gut's imbalanced ecosystem. This approach is built on the foundation of promising earlier research.

The confidence to launch a large-scale trial stems from the positive results of the company's Phase 2a 'TrIuMPH' study, announced in January 2026. In that trial of 122 patients with either constipation or diarrhea-predominant IBS, EBX-102-02 demonstrated clinically meaningful improvements in symptom severity compared to a placebo. Benefits in abdominal pain and bowel habits were seen as early as the first week and were sustained throughout the follow-up period.

Notably, a post-hoc analysis revealed a compelling responder rate: 51% of patients treated with EBX-102-02 experienced a significant reduction of at least 75 points on the IBS Symptom Severity Score, compared to just 33% of those on placebo. The therapy was also well-tolerated, with no serious drug-related adverse events reported, bolstering its safety profile ahead of later-stage development.

The 'RISE' Trial: A Pivotal Step Forward

The new £19 million in capital will directly fund the 'RISE' trial, a Phase 2b study designed to confirm the strong efficacy signals observed in the earlier trial. The study, officially named 'Restoring Intestinal Symbiosis for Efficacy in IBS', will be a randomised, double-blind, placebo-controlled trial enrolling approximately 300 patients with moderate-to-severe IBS-C across various sites in the United Kingdom.

Its scale makes it one of the largest interventional trials of a full-spectrum microbiome therapeutic ever conducted, reflecting the company's ambition and the strength of its preliminary data. Dosing for the first patient is expected in the second quarter of 2026, with crucial top-line efficacy data anticipated in the second half of 2027.

Dr James McIlroy, CEO of EnteroBiotix, commented on the trial's potential. “Following the positive outcome of our Phase 2a TrIuMPH trial... we are now commencing the largest ever full-spectrum microbiome therapeutic trial in IBS,” he stated. “The... RISE trial is designed to confirm the earlier signal observed and position EBX-102-02 as a potential first disease-modifying therapy for IBS-C, a highly debilitating condition that is estimated to affect over 10 million people in the USA and Europe, and where unmet need has persisted for decades.”

Scotland's Biotech Sector Gains Momentum

The substantial investment is not only a vote of confidence in EnteroBiotix but also a testament to Scotland's burgeoning life sciences sector. The backing from both a seasoned private investor like Thairm Bio and a mission-driven public body like the Scottish National Investment Bank highlights a powerful public-private partnership fueling innovation.

This funding arrives as the global microbiome therapeutics market is poised for explosive growth, with some analysts projecting it to surpass $3 billion by 2034. After years of being viewed as a high-risk sector, investor confidence is rising as companies like EnteroBiotix produce robust clinical data and establish clear regulatory pathways. The company's in-house GMP-certified manufacturing capabilities in Glasgow and Aberdeen further solidify its position, giving it end-to-end control over its product supply chain—a key strategic advantage in this emerging field.

For patients and physicians, the advancement of EBX-102-02 represents a tangible step toward a new paradigm in treating chronic gut conditions. While challenges such as the high placebo response often seen in IBS trials remain, the scientific rationale for microbial restoration is compelling. The RISE trial will be a critical test of whether this 'ecosystem reset' can finally offer the durable, disease-modifying relief that millions of patients have been waiting for.